Patritumab deruxtecan

Phase 3Antibody–drug conjugate

Merck & Co.

Patritumab deruxtecan is one of 193 biologic programs targeting Intestinal Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

192

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Malignant NeoplasmRecruiting

Gastrointestinal CancerRecruiting

Breast NeoplasmsRecruiting

Intestinal CancerPhase 1/Phase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

Malignant NeoplasmPreclinical

Recruiting

Gastrointestinal CancerPreclinical

Recruiting

Breast NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Patritumab deruxtecan

Merck & Co.

Phase 3

6 2

Prolia

Amgen

Preclinical

14 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

DATROWAY

Daiichi Sankyo

Preclinical

4 5

Megace

Bristol-Myers Squibb

Preclinical

4 6

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Breast Cancer

NCT05865990

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT05338970

Q4 2028

PreclinicalRecruiting

Gastrointestinal Cancer

NCT06596694

Q2 2029

Phase 2Recruiting

Solid Tumor

NCT06383884

Phase 1/2Recruiting

Breast Cancer

NCT06298084

Q3 2029

Phase 1/2Recruiting

Esophageal Adenocarcinoma

NCT06469944

Clinical

Trials by Indication[1]

Breast Cancer6 trials

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06797635·372 enrolled

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

Active, not recruiting·SSOLTI Breast Cancer Research Group·Phase 2·NCT05569811·120 enrolled

HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease

Active, not recruiting·MMedSIR·Phase 2·NCT05865990·63 enrolled

Show 3 more trials

Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT02980341·182 enrolled

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06686394·81 enrolled

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06298084·152 enrolled

Non-Small Cell Lung Cancer3 trials

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT07286149·190 enrolled

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT04619004·277 enrolled

TROPION-Lung02: Datopotamab Deruxtecan Combo in NSCLC

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT05338970·740 enrolled

Metastatic Colorectal Cancer1 trial

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT04479436·40 enrolled

Esophageal Adenocarcinoma1 trial

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT06469944·160 enrolled

Brain Metastases1 trial

A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases

Withdrawn·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 2·NCT05620914

4 more indications

Solid Tumor1 trial

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Recruiting·SSamsung Medical Center·Phase 2·NCT06383884·30 enrolled

Breast Neoplasms1 trial

An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07060807·1,000 enrolled

Gastrointestinal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06596694·180 enrolled

Malignant Neoplasm1 trial

LIGHTBEAM-U01 Substudy 01C: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06941272·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Patritumab deruxtecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Patritumab deruxtecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Patritumab deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Patritumab deruxtecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2028

Q2 2029

Q3 2029

Trials by Indication[1]

Breast Cancer6 trials

Non-Small Cell Lung Cancer3 trials

Metastatic Colorectal Cancer1 trial

Esophageal Adenocarcinoma1 trial

Brain Metastases1 trial

Solid Tumor1 trial

Breast Neoplasms1 trial

Gastrointestinal Cancer1 trial

Malignant Neoplasm1 trial

References

Drug Info

Quick Facts

Related News